1940 related articles for article (PubMed ID: 18509216)
21. [Consumption and cost of antipsychotic drugs].
Pérez J; Marín N; Vallano A; Castells X; Capellà D
Actas Esp Psiquiatr; 2005; 33(2):110-6. PubMed ID: 15768318
[TBL] [Abstract][Full Text] [Related]
22. [Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].
Bret P; Jolivel C; Bret MC; Veylit S; Martin C; Garcia P
Encephale; 1998; 24(4):365-77. PubMed ID: 9809242
[TBL] [Abstract][Full Text] [Related]
23. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment.
Neumann PJ
J Clin Psychiatry; 1999; 60 Suppl 3():9-14; discussion 15. PubMed ID: 10073371
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.
Ascher-Svanum H; Furiak NM; Lawson AH; Klein TM; Smolen LJ; Conley RR; Culler SD
J Med Econ; 2012; 15(3):531-47. PubMed ID: 22304338
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology and characteristics of emergency departments visits by US adults with psychiatric disorder and antipsychotic mention from 2000 to 2004.
Sankaranarayanan J; Puumala SE
Curr Med Res Opin; 2007 Jun; 23(6):1375-85. PubMed ID: 17594776
[TBL] [Abstract][Full Text] [Related]
26. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R; Cramer J; Xu W; Thomas J; Henderson W; Frisman L; Fye C; Charney D
N Engl J Med; 1997 Sep; 337(12):809-15. PubMed ID: 9295240
[TBL] [Abstract][Full Text] [Related]
27. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R; Cramer J; Xu W; Grabowski J; Douyon R; Thomas J; Henderson W; Charney D
Health Serv Res; 1998 Dec; 33(5 Pt 1):1237-61. PubMed ID: 9865219
[TBL] [Abstract][Full Text] [Related]
28. Formulary decisions and health economics.
Glazer WM
J Clin Psychiatry; 1998; 59 Suppl 19():23-9. PubMed ID: 9847049
[TBL] [Abstract][Full Text] [Related]
29. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
Sun SX; Liu GG; Christensen DB; Fu AZ
Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
[TBL] [Abstract][Full Text] [Related]
30. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.
Farley JF; Cline RR; Schommer JC; Hadsall RS; Nyman JA
Clin Ther; 2008 Aug; 30(8):1524-39; discussion 1506-7. PubMed ID: 18803994
[TBL] [Abstract][Full Text] [Related]
31. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
32. Outcome in schizophrenia: beyond symptom reduction.
Meltzer HY
J Clin Psychiatry; 1999; 60 Suppl 3():3-7; discussion 8. PubMed ID: 10073370
[TBL] [Abstract][Full Text] [Related]
33. Analysis of clinical characteristics and antipsychotic medication prescribing practices of first-episode schizophrenia in Israel: a naturalistic prospective study.
Strous RD; Bar F; Keret N; Lapidus R; Kosov N; Chelben J; Kotler M
Isr J Psychiatry Relat Sci; 2006; 43(1):2-9. PubMed ID: 16910378
[TBL] [Abstract][Full Text] [Related]
34. In the aftermath of CATIE: how should administrators value atypical antipsychotic medications?
Luchins DJ
Adm Policy Ment Health; 2006 Sep; 33(5):541-3. PubMed ID: 16688482
[TBL] [Abstract][Full Text] [Related]
35. The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting.
Ascher-Svanum H; Kennedy JS; Lee D; Haberman M
Am J Manag Care; 2004 Jan; 10(1):20-4. PubMed ID: 14738183
[TBL] [Abstract][Full Text] [Related]
36. Clinical redesign using all patient refined diagnosis related groups.
Sedman AB; Bahl V; Bunting E; Bandy K; Jones S; Nasr SZ; Schulz K; Campbell DA
Pediatrics; 2004 Oct; 114(4):965-9. PubMed ID: 15466092
[TBL] [Abstract][Full Text] [Related]
37. Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone.
Nightengale BS; Crumly JM; Liao J; Lawrence BJ; Jacobs EW
Psychopharmacol Bull; 1998; 34(3):373-82. PubMed ID: 9803771
[TBL] [Abstract][Full Text] [Related]
38. Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model.
Wang PS; Ganz DA; Benner JS; Glynn RJ; Avorn J
J Ment Health Policy Econ; 2004 Jun; 7(2):77-85. PubMed ID: 15208468
[TBL] [Abstract][Full Text] [Related]
39. Overview of the findings from the European SOHO study.
Suarez D; Haro JM
Expert Rev Neurother; 2008 Jun; 8(6):873-80. PubMed ID: 18505352
[TBL] [Abstract][Full Text] [Related]
40. Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
Leucht S; Kissling W; Davis JM
Psychol Med; 2009 Oct; 39(10):1591-602. PubMed ID: 19335931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
